Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OGN-TNFa
- Development stage
- Preclinical
- Lead developer
- OroGen BioSciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OGN-TNFa is a preclinical-stage small molecule inhibitor of Tumor Necrosis Factor alpha (TNFα) being developed by Orogen Therapeutics. The program is currently in the hit/lead optimization phase, with a primary focus on treating Rheumatoid Arthritis (RA). Unlike established biologic TNFα inhibitors, OGN-TNFa is a small molecule, which may offer distinct pharmacological properties or alternative routes of administration. The specific mechanism of action by which it modulates TNFα has not been fully disclosed, though it is intended to address the inflammatory pathways central to RA pathogenesis.
- Other names
- TNFα program
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on OGN-TNFa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OGN-TNFa.